Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Other financing activities (2020 - 2025)

Pulmonx (LUNG) has disclosed Other financing activities for 5 consecutive years, with $23000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other financing activities changed N/A to $23000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $76000.0, a 43.4% increase, with the full-year FY2022 number at $53000.0, up 29.27% from a year prior.
  • Other financing activities was $23000.0 for Q3 2025 at Pulmonx, down from $53000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $100000.0 in Q1 2021 to a low of -$59000.0 in Q2 2021.
  • A 3-year average of $29250.0 and a median of $38000.0 in 2022 define the central range for Other financing activities.
  • Biggest YoY gain for Other financing activities was 21.95% in 2021; the steepest drop was 102.5% in 2021.
  • Pulmonx's Other financing activities stood at -$59000.0 in 2021, then surged by 189.83% to $53000.0 in 2022, then crashed by 56.6% to $23000.0 in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Other financing activities are $23000.0 (Q3 2025), $53000.0 (Q4 2022), and -$59000.0 (Q2 2021).